natgillin/translations-raw huggingface dataset:
Three dogs had seizure-like activity; however, relation to treatment could not be established.
Trije psi so kazali aktivnost podobno seizmičnim krčem toda povezava z zdravljenjem ni bila dokazana.
Three doses
Trije odmerki
Three doses each of 0.5 ml at 0, 1, 6 months**
Trije odmerki po 0,5 ml pri 0, 1 in 6 mesecih
Three doses each of 0.5 ml, with first dose given at 2 months of age a
trije odmerki po 0,5 ml, prvi odmerek dan pri starosti 2 meseceva
Three doses of teduglutide, 0.0125 mg/kg/day (n=8), 0.025 mg/kg/day (n=14), and 0.05 mg/kg/day (n=15), were investigated for 12 weeks.
Dvanajst tednov so raziskovali tri odmerke teduglutida, 0,0125 mg/kg/dan (n=8), 0,025 mg/kg/dan (n=14) in 0,05 mg/kg/dan (n=15).
Three hypodermic safety needles
Tri hipodermični varnostni igli
Three implants per year are recommended, depending on the length of effect required.
Priporočajo se trije implantati na leto, kar je odvisno od trajanja potrebne zaščite.
Three Incivo tablets should be swallowed whole twice a day with food for a period of 12 weeks.
Tri tablete zdravila Incivo je treba jemati 12 tednov, in sicer jih je treba pogoltniti cele s hrano dvakrat na dan.
Three independent, open-label, single arm, investigator-initiated studies with Myozyme were conducted:
Na pobudo raziskovalca so izvedli tri neodvisne, odprte študije z zdravilom Myozyme z eno skupino preiskovancev:
Three inserts, each with two 43.7mm openings per insert must be used.
Uporabiti morate tri vstavke, vsakega z dvema 43,7-milimetrskima odprtinama.
Three main studies involving 1,178 patients with hepatitis C virus of genotype 1 investigated the combination with peginterferon alfa and ribavirin.
V treh glavnih študijah pri 1 178 bolnikih z virusom hepatitisa C genotipa 1 so proučevali kombinacijo z peginterferonom alfa in ribavirinom.
Three main studies involving 107 adults found that Pandemic influenza vaccine H5N1 MedImmune was able to prepare the immune system to defend itself against the H5N1 virus strain in individuals who had never come into contact with it.
Tri glavne študije, v katere je bilo vključenih 107 odraslih, so pokazale, da lahko cepivo proti pandemski gripi H5N1 MedImmune pripravi imunski sistem oseb, ki niso bile nikoli izpostavljene sevu virusa H5N1, da se brani pred njim.
Three main studies were carried out in adults with schizoaffective disorder.
Pri odraslih s shizoafektivno motnjo so bile izvedene tri glavne študije.
Three main studies were carried out with M-M-RVAXPRO.
S cepivom M-M-RVAXPRO so bile opravljene tri glavne študije.
Three main studies were performed, involving a total of 1,050 adults with partial-onset seizures that were not controlled by other medicines.
Izvedene so bile tri glavne študije, ki so vključevale 1 050 odraslih z napadi parcialnega izvora, ki niso bili zdravljeni z drugimi zdravili.
Three major forms of interferons have been distinguished: alpha, beta and gamma.
Poznamo tri glavne vrste interferonov: alfa, beta in gama.
Three measuring spoons (green, pink, blue,) dispense, 100mg, 150mg or 1g of betaine anhydrous.
Priložene so tri merilne žličke (zelena, rožnata, modra), s katerimi odmerimo 100 mg, 150 mg ali 1 g brezvodnega betaina.
Three measuring spoons (pink, blue, green) dispense, respectively, 1 g, 150 mg and 100 mg of betaine anhydrous.
Priložene so tri merilne žličke (rožnata, modra, zelena), s katerimi odmerimo 1 g, 150 mg in 100 mg brezvodnega betaina.
Three metabolites have been detected in human plasma at netupitant oral doses of 30 mg and higher (the desmethyl derivative, M1; the N-oxide derivative, M2; the OH-methyl derivative, M3).
Pri peroralnih odmerkih netupitanta 30 mg ali večjih so v človeški plazmi zaznali tri presnovke (derivat desmetila M1, derivat N-oksida M2 in derivat OH-metila M3).
Three months therapy with degarelix (240/80 mg dose regimen) resulted in a 37% reduction in prostate volume as measured by trans-rectal ultrasound scan (TRUS) in patients requiring hormonal therapy prior to radiotherapy and in patients who were candidates for medical castration.
Trimesečno zdravljenje z degareliksom (v odmerku 240/80 mg) je zmanjšalo velikost prostate za 37 %, izmerjeno s transrektalnim ultrazvokom (TRUZ), pri bolnikih, ki so pred radioterapijo potrebovali hormonsko zdravljenje, in bolnikih, ki so bili primerni za medicinsko kastracijo.
Three multi-centre, open-labelled, non-controlled trials have been conducted to evaluate the safety and efficacy of NovoEight in the prevention and treatment of bleeds in previously treated patients with severe haemophilia A (FVIII activity ≤1%).
Za oceno varnosti in učinkovitosti zdravila NovoEight za preprečevanje in zdravljenje krvavitev pri predhodno zdravljenih bolnikih s hudo hemofilijo A (aktivnost FVIII ≤ 1 %) so bila izvedena 3 multicentrična, odprta, nekontrolirana preskušanja.
Three of 8 (37.5%) paediatric patients <7 years of age experienced at least one infusion related reaction over a mean observation time of 4.2 years.
Trije od 8 (37,5 %) pediatričnih bolnikov, mlajših od 7 let, so imeli vsaj eno reakcijo, povezano z infundiranjem, v srednjem času opazovanja 4,2 let.
Three of the efavirenz treatment failure isolates tested remained sensitive to efavirenz in cell culture and were also sensitive to nevirapine and delavirdine.
Trije od teh testiranih izolatov iz neuspešnega zdravljenja z efavirenzem so ostali občutljivi na efavirenz v celični kulturi in so bili občutljivi tudi na nevirapin in delavirdin.
Three of the Phase 3 studies (PIPF-004, PIPF-006, and PIPF-016) were multinational, and one (SP3) was conducted in Japan.
Tri od študij faze III (PIPF–004, PIPF–006 in PIPF–016) so bile mednarodne, eno (SP3) pa so izvedli na Japonskem.
Three of these studies (NB-301, NB-302 and NB-304) designated the primary endpoint at 56 weeks, and 1 study (NB-303) designated the primary endpoint at week 28, but continued for 56 weeks.
V treh od teh študij (NB-301, NB-302 in NB-304) je bil primarni cilj ovrednoten v 56. tednu, v eni študiji (NB-303) pa je bil primarni cilj ovrednoten v 28. tednu, a se je študija nadaljevala do 56. tedna.
Three of these studies included some patients treated with other antidepressants, either fluoxetine or paroxetine, as an ‘active comparator’.
Tri od teh študij so vključevale nekaj bolnikov, zdravljenih z drugimi antidepresivi, in sicer s fluoksetinom ali paroksetinom kot „aktivnim primerjalnim zdravilom“.
Three of these studies involving 1,411 patients compared Multaq with placebo (a dummy treatment).
V treh od teh študij so zdravilo Multaq pri 1 141 bolnikih primerjali s placebom (zdravilom brez zdravilne učinkovine).
Three or more monthly injections may be needed.
Morda bo tri ali več zaporednih mesecev potrebna 1 injekcija na mesec.
Three oral syringes (1 ml, 3 ml and 5 ml) are provided for accurate measurement of the prescribed dose.
Za natančno merjenje predpisanega omerka so priložene tri brizge za peroralno dajanje (1 ml, 3 ml in 5 ml).
Three pack sizes are available for Norvir tablets:
Norvir filmsko obložene tablete so na voljo v treh pakiranjih:
Three pack-sizes of Vargatef 100 mg soft capsules are available:
Na voljo so tri velikosti pakiranj zdravila Vargatef 100 mg mehke kapsule:
Three patients (0.3%) experienced QTcF interval prolongation (greater than 500 ms).
Pri treh bolnikih (0,3 %) se je pojavilo podaljšanje intervala QTcF (večje od 500 ms).
Three patients from the single institution study and 15 patients from the multicentre study had stem cell transplants after completing TRISENOX.
Trem bolnikom iz enocentrične študije in 15 bolnikom iz multicentrične študije so po koncu zdravljenja z zdravilom TRISENOX transplantirali zarodne celice.
Three patients had values above the upper limit of quantification (5 ng/mL) however they were already taking oral ciclosporin at a stable dose, which was allowed by the studies’ protocol.
Trije bolniki so imeli vrednosti nad zgornjo mejo kvantifikacije (5 ng/ml), vendar so že jemali stabilni odmerek peroralnega ciklosporina, kar je protokol študij dopuščal.
Three patients in the MabThera subcutaneous formulation trial SABRINA (BO22334) were inadvertently administered subcutaneous formulation through the intravenous route up to a maximum rituximab dose of 2780 mg with no untoward effect.
V preskušanju s podkožno obliko zdravila MabThera SABRINA (BO22334) so trem bolnikom podkožno obliko zdravila pomotoma dali intravensko do maksimalnega odmerka rituksimaba 2780 mg, a brez škodljivih učinkov.
Three patients in the MabThera subcutaneous NHL formulation trial SABRINA (BO22334) were inadvertently adminstered subcutaneous formulation through the intravenous route up to a maximum rituximab dose of 2780 mg with no untoward effect.
V preskušanju s podkožno obliko zdravila MabThera SABRINA (BO22334) pri zdravljenju NHL so trem bolnikom podkožno obliko zdravila pomotoma dali intravensko do maksimalnega odmerka rituksimaba 2780 mg, a brez škodljivih učinkov.
Three patients in the Pradaxa group died (less than 1%), but two of these deaths were unrelated to blood clots.
Umrli so trije bolniki (manj kot 1 %), ki so prejemali zdravilo Pradaxa, vendar dve od teh smrti nista bili povezani s krvnimi strdki.
Three patients presented a complete haematological response (CHR) and one patient experienced a partial haematological response (PHR).
Trije bolniki so dosegli popolni hematološki odziv (CHR), en bolnik pa je dosegel delni hematološki odziv (PHR - partial haematological response).
Three patients presented a complete haematological response (CHR) and one patient experienced a partial haematological response (PHR).
Trije bolniki so dosegli popolni hematološki odziv (CHR), en bolnik pa je dosegel delni hematološki odziv (PHR).
Three pivotal studies were conducted to assess the efficacy and safety of NEVANAC dosed 3 times daily as compared to vehicle and/or ketorolac trometamol in the prevention and treatment of postoperative pain and inflammation in patients undergoing cataract surgery.
Opravljene so bile tri ključne študije za oceno varnosti in učinkovitosti zdravila NEVANAC, ki so si ga bolniki odmerili v oko 3-krat na dan, v primerjavi z vehiklom in/ali ketorolak trometamolom za preprečevanje in zdravljenje pooperativne bolečine in vnetja pri bolnikih, ki so imeli operacijo katarakte.
Three Pixuvri patients (4.4%) had tachycardia, arrhythmia, sinus tachycardia, or bradycardia.
Pri treh bolnikih, ki so prejemali zdravilo Pixuvri (4,4 %), so se pojavili tahikardija, aritmija, sinusna tahikardija ali bradikardija.
Three placebo-controlled phase III studies in plaque psoriasis were integrated to evaluate the safety of Taltz in comparison to placebo up to 12 weeks after treatment initiation.
Tri študije 3. faze, nadzorovane s placebom, o psoriazi s plaki so bile vključene za oceno varnosti zdravila Taltz v primerjavi s placebom do 12 tednov po uvedbi zdravljenja.
Three presentations are available:
Na voljo so naslednja tri pakiranja:
Three presentations are available:
Na voljo so tri pakiranja:
three pump actuations
trije pritiski navzdol
Three recommended injection sites for Enbrel using a pre-filled syringe include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 1).
Za injiciranje napolnjene injekcijske brizge zdravila Enbrel so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 1).
Three recommended injection sites for Nplate include:
Med tremi priporočenimi mesti za injiciranje zdravila Nplate so:
Three separate 5-day treatments must be performed at day 0, day 14 and day 60.
Izvesti se morajo tri ločena 5 dnevna zdravljenja z začetkom na 0., 14. in 60. dan.
Three side effects are possibly related to the medicine’s toxic effect on mitochondria (the energy- producing components within cells): lipoatrophy, lactic acidosis (a build-up of lactic acid in the body) and peripheral neuropathy.
Trije neželeni učinki so verjetno povezani s toksičnim učinkom zdravila na mitohondrije (dele v celicah, ki proizvajajo energijo): lipoatrofija, aktacidoza (kopičenje mlečne kisline v telesu) in periferna nevropatija.
Three studies compared Incruse with placebo (a dummy treatment), while one study compared Incruse with tiotropium (another medicine for COPD).
V treh študijah so zdravilo Incruse primerjali s placebom (zdravilom brez zdravilne učinkovine), v eni študiji pa so ga primerjali s tiotropijem (drugim zdravilom za zdravljenje KOPB).
Three studies looked at the effects of giving Herceptin earlier in treatment, in combination with chemotherapy.
V treh študijah so proučevali učinke dajanja zdravila Herceptin na začetku zdravljenja v kombinaciji s kemoterapijo.
Three studies were conducted in men to assess the potential effect on spermatogenesis of CIALIS 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily.
Pri moških so izvedli tri študije za ugotavljanje možnega učinka zdravila CIALIS 10 mg (ena 6- mesečna študija) in 20 mg (ena 6-mesečna in ena 9-mesečna študija), ki so ga dajali dnevno, na spermatogenezo.
Three studies were conducted in men to assess the potential effect on spermatogenesis of tadalafil 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily.
Pri moških so izvedli tri študije za ugotavljanje možnega učinka tadalafila 10 mg (ena 6- mesečna študija) in 20 mg (ena 6-mesečna in ena 9-mesečna študija), ki so ga dajali dnevno, na spermatogenezo.
Three studies were conducted in men to assess the potential effect on spermatogenesis of tadalafil 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily.
Pri moških so izvedli tri študije za ugotavljanje možnega učinka tadalafila 10 mg (ena 6-mesečna študija) in 20 mg (ena 6-mesečna in ena 9-mesečna študija), ki so ga dajali dnevno, na spermatogenezo.
Three studies were conducted in men to assess the potential effect on spermatogenesis of tadalafil 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily.
Pri moških so izvedli tri študije za ugotavljanje možnega učinka zdravila Tadalafil Mylan 10 mg (ena 6- mesečna študija) in 20 mg (ena 6-mesečna in ena 9-mesečna študija), ki so ga dajali dnevno, na spermatogenezo.
Three studies were ‘open’, meaning that the medicine was not compared to any other treatment and the patients knew that they were receiving Hycamtin.
Tri študije so bile „odprte“, kar pomeni, da zdravila niso primerjali z nobenim drugim zdravljenjem in da so bolniki vedeli, da prejemajo zdravilo Hycamtin.
Three subcutaneous 140 mg doses were bioequivalent to a single subcutaneous 420 mg dose.
Trije subkutani odmerki po 140 mg so bili bioekvivalentni enemu subkutanemu odmerku 420 mg.
Three subjects had undetectable viral load and one had plasmatic HIV-RNA of 900 copies/ml at Week 48.
Trije preiskovanci so imeli 48. teden nezaznavno virusno obremenitev, eden pa je imel HIV-RNA v plazmi 900 kopij/ml.
Three therapeutic studies performed in PD patients without any tyramine restriction, also did not detect any evidence of tyramine potentiation.
V treh terapevtskih študijah pri bolnikih s parkinsonovo boleznijo, opravljenih brez omejitve tiramina, prav tako ni bilo dokazov o potenciranju učinka tiramina.
Three times a day
trikrat na dan
Three times per day
Trikrat na dan.
Three to six months are required after the initiation of therapy for equilibration to occur.
Ravnovesje dosežete po treh do šestih mesecih po začetku zdravljenja.
Three to six months are required after the initiation of therapy for equilibration to occur.
Ravnovesne koncentracije dosežemo po treh do šestih mesecih po začetku zdravljenja.
Three tubes of breath are to be taken, which are used to measure the presence of excess levels of 13C, which will be present if the patient is H. pylori positive.
Vzeti je treba tri epruvete z vzorci, ki se jih uporabljajo za merjenje prisotnosti povišanega nivoja 13C, ki bi bil prisoten, če je bolnik H. pylori pozitiven.
Three years data showed a decrease in the incidence of gout flares with less than 4% of patients requiring treatment for a flare (i.e. more than 96% of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36.
Triletni podatki so pokazali zmanjšanje napadov protina in manj kot 4 % bolnikov je potrebovalo nadaljnjo zdravljenje izbruhov protina (tj. več kot 96 % bolnikov ni bilo potrebno zdraviti zaradi napadov protina) v mesecih od 16 do 24 in v mesecih od 30 do 36.
Three, 6 month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136).
Pri dializnih bolnikih s končno odpovedjo ledvic in neobvladanim sekundarnim hiperparatiroidizmom (N = 1.136) so opravili tri 6-mesečne, dvojno slepe, s placebom nadzorovane klinične študije.
Three, 6-month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136).
Pri dializnih bolnikih s končno odpovedjo ledvic in neobvladanim sekundarnim hiperparatiroidizmom (N = 1.136) so opravili tri 6-mesečne, dvojno slepe, s placebom nadzorovane klinične študije.
Three-dose primary series
Primarno zaporedje cepljenja s tremi odmerki
Three-sigma threshold value
Mejna vrednost treh sigem
throat and mouth yeast infection vaginal infection
glivična okužba žrela in ustne votline, okužba nožnice.
throat infection
okužba žrela,
throat infections  dry eyes
okužbe grla  suhe oči
throat inflammation
vnetje grla
throat inflammation that causes a hoarse voice
vnetje grla, ki povzroči hripav glas
throat inflammation that causes a hoarse voice;
vnetje grla, ki povzroči hripav glas;
Throat irritation
draženje grla
throat irritation
draženje grla/žrela
throat irritation
draženje v grlu
Throat irritation
draženje v žrelu
Throat irritation
Draženje žrela
Throat irritation
draženje žrela hripavost/disfonija sinusitis
Throat irritation
draženje žrela,
Throat irritation
vnetje grla oziroma žrela
Throat irritation
vnetje žrela
Throat irritation
vnetje žrela oziroma grla
throat irritation, throat tightness, lip swelling, tongue swelling injection site discolouration, injection site itching and discolouration
draženje grla, stiskanje v grlu, oteklost ustnic, oteklost jezika obarvanje mesta injiciranja, srbenje in obarvanje mesta injiciranja
throat irritation2, nasal dryness1, postnasal drip1, sneezing2 Not known: asthma2
Meibomovih žlez2, diplopija2, bleščanje2, hipestezija očesa2, pigmentacija beločnice2, subkonjunktivalna cista2, neobičajen občutek v očesu1, astenopija1
Throat pain
boleče žrelo,
throat pain
bolečina v grlu
throat pain
bolečina v žrelu,
throat pain or irritation
bolečine ali draženje v žrelu,
Throat pain, snoring
bolečina v žrelu, smrčanje
throat redness*
rdečina žrela*,
Throat tightness
tiskanje v grlu
Throat tightness Epistaxis
gastroenteritis
Throat tightness Epistaxis
Gastrointestina lna krvavitev
Throat tightness Epistaxis
stisnjeno grlo epistaksa
Throat tightness Epistaxis
stisnjeno grlo, epistaksa
throat tightness generalized itching
tiskanje v vratu, srbenje po vsem telesu.
Throat tightness, hiccups, throat irritation,
stiskanje v grlu, kolcanje, draženje žrela
Throat tightness, Nasal oedema, Nasal dryness
tiskanje v grlu, edem nosu, suha nosna sluznica
throat tightness, nose bleeds
napeto grlo, krvavitve iz nosu
throat tightness, nose bleeds;
napeto grlo, krvavitve iz nosu;
Throat tightness, throat irritation, cough
stiskanje v grlu, draženje grla, kašelj
throat tightness, throat irritation, cough
tiskanje v grlu, draženje grla, kašelj
Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross- linked framework that stabilises the thrombus.
Trombin ima osrednjo vlogo pri trombotskem procesu, saj fibrinogen cepi na monomere fibrina in aktivira faktor XIII v faktor XIIIa, kar fibrinu omogoča, da razvije kovalentno premreženo ogrodje, ki stabilizira trombus.
Thrombo- cytopaenia; Anaemia; Leucopenia
trombocitopenija, anemija, levkopenija
Thrombo- cytopenia
Trombocito penija
Thrombo- cytopeniaa
trombo- citopenijaa
Thrombo- cytopeniaa
trombocito- penijaa
Thrombo- embolism (venous)b,d
renalna trombotična mikroangio- patija a,b
Thrombo-embolism
Tromboembolija
Thrombocyt
trombocitop enija
Thrombocyte count
Število trombocitov
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
število trombocitov ≥ 100 x 109/l, skupna merila toksičnosti (SMT) za nehematološko toksičnost ≤ 1. stopnje (z izjemo alopecije, slabosti in bruhanja).
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
število trombocitov ≥ 100 x 109/l, splošna merila toksičnosti za nehematološko toksičnost ≤ stopnja 1 (razen za alopecijo, navzejo in bruhanje).
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
število trombocitov ≥ 100 x 109/l; skupna merila toksičnosti (SMT) za nehematološko toksičnost ≤ 1. stopnje (z izjemo alopecije, navzee in bruhanja).
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
število trombocitov ≥100 x 109/l, skupna merila toksičnosti (SMT) za nehematološko toksičnost ≤ stopnje 1 (razen alopecije, slabosti in bruhanja).
Thrombocythaemia Splenomegaly Lymphadenopathy Hypochromasia
trombocitemija splenomegalija limfadenopatija hipokromazija
Thrombocythaemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy
trombocitemija, limfopenija, depresija kostnega mozga, eozinofilija,
Thrombocythaemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy
trombocitemija, limfopenija, depresija kostnega mozga, eozinofilija, limfadenopatija
Thrombocythemia
trombocitemija
Thrombocythemia (incl. platelet count increased)A
trombocitemija (vključno s povečanim številom trombocitov)A
thrombocyto
trombocito
Thrombocyto penia11
Trombocitopenija11
Thrombocyto- penia
trombocito- penija
thrombocytopaenia (1.3% vs 1.5%), anaemia (4.0% vs
trombocitopenija (1,3% v primerjavi z 1,5%), anemija (4,0% v primerjavi s 3,8%)
Thrombocytopaenia (decrease in platelets) a, b
trombocitopenija (zmanjšanje števila trombocitov)a, b
Thrombocytopaenia occurring after first exposure to a GPIIb/IIIa inhibitor may be explained by the fact that antibodies are naturally present in some normal individuals.
Trombocitopenijo, ki se pojavi po prvi izpostavljenosti zaviralcu GPIIb/IIIa, je mogoče pojasniti s tem, da so protitelesa pri nekaterih zdravih osebah naravno prisotna .
Thrombocytopaenia, including acute profound thrombocytopaenia, has been observed with eptifibatide administration post-marketing (see section 4.8)
Pri uporabi eptifibatida v obdobju trženja so opažali trombocitopenijo, vključno z akutno hudo trombocitopenijo (glejte poglavje 4.8).
Thrombocytopaenia, including acute profound thrombocytopaenia, has been observed with eptifibatide administration post-marketing (see section 4.8).
Pri uporabi eptifibatida v obdobju trženja so opažali trombocitopenijo, vključno z akutno hudo trombocitopenijo (glejte poglavje 4.8).
Thrombocytopaenia, lymphadenopathy, lymphopenia
trombocitopenija, limfadenopatija, limfopenija
Thrombocytopaenia, neutropaenia, and anaemia
Trombocitopenija, nevtropenija in anemija
Thrombocytope
limfocitoza
Thrombocytope nia11
Trombocitopenija
Thrombocytope nia11
Trombocitopenija11
Thrombocytopeni a11
Trombocitope nija11
Thrombocytopeni a11
Trombocitopenija11
Thrombocytopeni a; Leukopenia, Pancytopenia
trombocitopenija, levkopenija, pancitopenija
Thrombocytopenia
Anemija Trombocitopenija
Thrombocytopenia
istema
Thrombocytopenia
Trombocito penija11
Thrombocytopenia
Trombocitop enija11
Thrombocytopenia
trombocitopenija
Thrombocytopenia
trombocitopenija,